Different Outcome in COVID-19 Patients with or without PPI Use: A Systematic Review and Meta-analysis
I Made, Wisnu Wardhana, Saraswati Laksmi Dewi
Background The coronavirus disease (COVID-19) pandemic still happening and when it's going to be resolved is not known. In this COVID-19 era, physicians need to better understand the risk and purpose of giving drugs that patients do not need. Proton pump inhibitors (PPI) are sometimes easily prescribed and misused by physicians. The study objective is to find out whether PPI use is associated with better or worse outcomes in patients with COVID-19.
Method We searched retrospective studies in various publication libraries like PubMed, Embase, and CENTRAL from 2020 to 2022. Inclusion criteria were studied which differentiated patients with COVID-19 who regularly used PPI and control which is COVID-19 patients who did not use PPI. That study also needs to report the outcomes. The outcome was then divided into two categories which are good outcomes and worse outcomes consisting of severe COVID-19 needing oxygen therapy, admission to intensive care unit (ICU), acute respiratory distress syndrome (ARDS), shock or mortality, to get each study and total odd ratio (OR), 95% confidence interval, and weight. Studies that did not report the outcomes were excluded. We also analyze the data using a fixed or random effect model accordingly and asses the possibility of publication bias using Egger's test. Case Seven of 11 studies with more than 30.000 COVID-19 patients were analyzed in this study. These patients were divided into 2 groups: patients with COVID-19 who were using PPI up to 30 days before being infected and COVID-19 patients who didn't use PPI before. The total number of patients in the first group is 3531 patients and the second group is 38138 patients. After statistical analysis, we found that the data is heterogenous with p <0,05, I2 94,22% (95%CI 90,44-96,51%) suggesting the OR needs to be determined in the random effect model. We found that pooled OR is 1.99 (p 0.01, 95% CI, 1.18-3.38). Egger's test for the possibility of publication bias is 0,64 (95%CI -7,24-4,93). Conclusion COVID-19 patients who use PPI are twice as likely to have a worse outcome than COVID-19 patients who don't use PPI. This study is statistically significant with a low possibility of publication bias.
Author contributions IMWW write the full text, IMWW and SLD search the online publication library and review all related articles, IMWW and SLD make the metaanalysis. All authors review the full text.
Conflict of interest None to be disclosed
References
Argenziano, Bruce, Slater, Tiao, Baldwin et al., Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, BMJ
Buendgens, Bruensing, Matthes, Dückers, Luedde et al., The administration of proton pump inhibitors in critically ill medical patients is associated with an increased risk of developing Clostridium difficile-associated diarrhoea, J Crit Care
Dial, Proton pump inhibitor use and enteric infections, Am J Gastroenterol
Hariyanto, Prasetya, Kurniawan, Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection, Digestive and liver disease
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Israelsen, Ernst, Lundh, Lundbo, Sandholdt et al., Proton Pump Inhibitor Use Is Not Strongly Associated With SARS -CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc
Johnson, Harris, Cain, Hummer, Goyal et al., pulmonary and extra-pulmonary clinical manifestations of COVID-19, Front Med
Laheij, Sturkenboom, Hassing, Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs, JAMA
Lee, Ha, Yeniova, Moon, Kim, Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, Gut,
doi:10.1136/gutjnl-2020-322248Lee, Ha, Yeniova, Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, GUT
Liberati, Altman, Tetzlaff, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Ann Intern Med
Luxenburger, Sturm, Biever, Rieg, Duerschmied, Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor, JIM
Mckeigue, Kennedy, Weir, Bishop, Mcgurnaghan et al., Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study, medRxiv,
doi:.org/10.1101/2020.07.23.20160747Nguyen, Islam, Galvin, Chang, Sy et al., Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia, International Journal for Quality in Health Care,
doi:10.1093/intqhc/mzaa041Pranata, Huang, Lawrensia, Henrina, Lim et al., Proton pump inhibitor on susceptibility to COVID-19 and its severity: A systematic review and meta-analysis, Pharmacol. Rep,
doi:10.1007/s43440-021-00263-xRamachandran, Perisetti, Gajendran, Jean-Loius, Bansal, Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19, medRxiv,
doi:10.1101/2020.07.12.20151084Stroup, Berlin, Morton, Metaanalysis of observational studies in epidemiology: a proposal for reporting, JAMA
Ullah, Sivapalan, Kocher, Chelala, COVID-19 in patients with hepatobiliary and pancreatic diseases: A single-centre cross-sectional study in East London, Pancreatology
Wells, Shea, 'connell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
Xie, Bowe, Yan, Estimates of all-cause mortality and cause-specific mortality associated with proton pump inhibitors among US veterans: cohort study, BMJ
Zhou, Wang, Lee, Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study, Gut Epub ahead of print,
doi:10.1136/gutjnl-2020-323668{ 'indexed': {'date-parts': [[2024, 6, 21]], 'date-time': '2024-06-21T00:25:18Z', 'timestamp': 1718929518958},
'reference-count': 0,
'publisher': 'Universitas Warmadewa',
'issue': '1',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>Background The coronavirus disease (COVID-19) pandemic still happening and when '
'it’s going to be resolved is not known. In this COVID-19 era, physicians need to better '
'understand the risk and purpose of giving drugs that patients do not need. Proton pump '
'inhibitors (PPI) are sometimes easily prescribed and misused by physicians. The study '
'objective is to find out whether PPI use is associated with better or worse outcomes in '
'patients with COVID-19.\r\n'
'Method We searched retrospective studies in various publication libraries like PubMed, '
'Embase, and CENTRAL from 2020 to 2022. Inclusion criteria were studied which differentiated '
'patients with COVID-19 who regularly used PPI and control which is COVID-19 patients who did '
'not use PPI. That study also needs to report the outcomes. The outcome was then divided into '
'two categories which are good outcomes and worse outcomes consisting of severe COVID-19 '
'needing oxygen therapy, admission to intensive care unit (ICU), acute respiratory distress '
'syndrome (ARDS), shock or mortality, to get each study and total odd ratio (OR), 95% '
'confidence interval, and weight. Studies that did not report the outcomes were excluded. We '
'also analyze the data using a fixed or random effect model accordingly and asses the '
'possibility of publication bias using Egger’s test.\r\n'
'Case Seven of 11 studies with more than 30.000 COVID-19 patients were analyzed in this study. '
'These patients were divided into 2 groups: patients with COVID-19 who were using PPI up to 30 '
'days before being infected and COVID-19 patients who didn’t use PPI before. The total '
'number of patients in the first group is 3531 patients and the second group is 38138 '
'patients. After statistical analysis, we found that the data is heterogenous with p <0,05, '
'I2 94,22% (95%CI 90,44-96,51%) suggesting the OR needs to be determined in the random effect '
'model. We found that pooled OR is 1.99 (p 0.01, 95% CI, 1.18-3.38). Egger’s test for the '
'possibility of publication bias is 0,64 (95%CI -7,24-4,93).\r\n'
'Conclusion COVID-19 patients who use PPI are twice as likely to have a worse outcome than '
'COVID-19 patients who don’t use PPI. This study is statistically significant with a low '
'possibility of publication bias.</jats:p>',
'DOI': '10.22225/ijbstm.1.1.2024.19-23',
'type': 'journal-article',
'created': {'date-parts': [[2024, 6, 20]], 'date-time': '2024-06-20T06:42:16Z', 'timestamp': 1718865736000},
'page': '19-23',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Different Outcome in COVID-19 Patients with or without PPI Use: A Systematic Review and '
'Meta-analysis',
'prefix': '10.22225',
'volume': '1',
'author': [ {'given': 'I Made Wisnu', 'family': 'Wardhana', 'sequence': 'first', 'affiliation': []},
{'given': 'Saraswati Laksmi', 'family': 'Dewi', 'sequence': 'additional', 'affiliation': []}],
'member': '9632',
'published-online': {'date-parts': [[2024, 3, 30]]},
'container-title': 'International Journal of Biomedical Science and Travel Medicine',
'original-title': [],
'link': [ { 'URL': 'https://www.ejournal.warmadewa.ac.id/index.php/ijbstm/article/download/9176/5450',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.ejournal.warmadewa.ac.id/index.php/ijbstm/article/download/9176/5450',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 6, 20]],
'date-time': '2024-06-20T06:42:19Z',
'timestamp': 1718865739000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.ejournal.warmadewa.ac.id/index.php/ijbstm/article/view/9176'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 3, 30]]},
'references-count': 0,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 3, 30]]}},
'URL': 'http://dx.doi.org/10.22225/ijbstm.1.1.2024.19-23',
'relation': {},
'ISSN': ['3047-7433', '3047-7441'],
'subject': [],
'container-title-short': 'ijbstm',
'published': {'date-parts': [[2024, 3, 30]]}}
